Skip to main content

Table 1 The general characteristic of the included studies

From: Comparative efficacy and safety of different hemostatic methods in total hip arthroplasty: a network meta-analysis

Study

Sample size

Comparators

Study design

Male, %

Mean age

Bone cement

Dose

Benoni 2000

40 (20/20)

IV TXA/C

RCT

42.5

69.5/68

Cemented

10 mg/kg TXA

Ekbäck 2000

40 (20/20)

IV TXA/C

RCT

50

66.4/65.6

Cemented

10 mg/kg TXA

Ido 2000

40 (20/20)

IV TXA/C

RCT

NS

NS

Cemented

1000 mg TXA

Husted 2003

40 (20/20)

IV TXA/C

RCT

32.5

65/67

Cementless or hybird

10 mg/kg TXA

Lemay 2004

39 (20/19)

IV TXA/C

RCT

64.1

59.7/53.6

Cemented or cementless

10 mg/kg TXA

Garneti 2004

50 (25/25)

IV TXA/C

RCT

NS

67.6/69.6

Cemented

10 mg/kg TXA

Yamasaki 2004

40 (20/20)

IV TXA/C

RCT

67.5

55.5/61.2

Cementless

1 g TXA

Johansson 2005

100 (47/53)

IV TXA/C

RCT

43

69/68

Cemented

15 mg/kg TXA

Niskanen 2005

39 (19/20)

IV TXA/C

RCT

33.3

66/65

Cemented

10 mg/kg TXA

Claeys 2007

40 (20/20)

IV TXA/C

RCT

30

73/68

Hybrid

15 mg/kg TXA

Rajesparan 2009

73 (36/37)

IV TXA/C

RCT

35.6

67.5/67.7

Cemented, cementless or Hybrid

1 g TXA

Kazemi 2010

64 (32/32)

IV TXA/C

RCT

67.2

46.6/45.4

Cementless

15 mg/kg TXA

Singh 2010

42 (21/21)

IV TXA/C

RCT

45.2

69/73

Cemented or cementless

10 mg/kg TXA

McConnell 2011

66 (22/22/2)

IV TXA/FS/C

RCT

31.8

NS

Cemented

10 mg/kg TXA/10 ml FS

Malhotra 2011

50 (25/25)

IV TXA/C

RCT

44

52.6/54.7

Cementless

15 mg/kg TXA

Clave 2012

70 (37/33)

IV TXA/C

RCT

35.7

69/73

Cementless

1 g TXA

Norio 2012

117 (95/22)

IV TXA/C

RCT

17.9

64.4/60.2

Cementless

1 g TXA

Falez 2013

69 (31/38)

FS/C

RCT

NS

NS

Cementless

10 ml FS

Lassen 2006

69 (33/36)

FS/C

RCT

39.1

67.1/63.1

Cemented or cementless

NS

Mawatari 2006

100 (50/50)

FS/C

RCT

NS

60/60

Cementless

10 ml FS

Randelli F 2013

70 (35/35)

FS/C

RCT

41.2

63.1/64.2

Cementless

10 ml FS

Wang 2003

81 (38/43)

FS/C

RCT

54.2

66.9/67.8

NS

10 ml FS

Xie 2016

140 (70/70)

IV TXA/T TXA

RCT

45

59.5/62.2

Cementless

1.5g IV TXA/3g T TXA

Wei 2014

303 (100/102/101)

IV TXA/T TXA/C

RCT

37.3

63.6/60.2/63.9

Cementless

3g IV TXA/3g T TXA

North 2016

139 (70/69)

IV TXA/T TXA

RCT

55.5

64.1/65.7

Cementless

2g IV TXA/2 g T TXA

Zhang 2016

75 (25/25/25)

IV TXA/T TXA/C

RCT

52

44.5/44.3/43.4

Cementless

1g IV TXA/1 g T TXA

Martin 2013

50 (25/25)

T TXA/C

RCT

38.7

62.9/63.9

Cemented

2g T TXA

Alshryda 2013

161 (80/81)

T TXA/C

RCT

45.9

66/63

Cementless

NS

Yue 2014

101 (52/49)

T TXA/C

RCT

52.1

60.9/63.7

Cementless

3 g T TXA

Yi 2016

100 (50/50)

IV TXA/C

RCT

53

54/56.6

NS

15 mg/kg TXA

Lee 2013

68 (34/34)

IV TXA/C

RCT

NS

51.4/52.8

Cementless

15 mg/kg TXA

Benoni 2001

38 (18/20)

IV TXA/C

RCT

50

66/68

Cemented

10 mg/kg TXA

  1. IV intravenous, T topical, TXA tranexamic acid, C control, FS fibrin sealant, NS not stated, RCT randomized controlled trials